ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (OTC BB: RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that it has been awarded a grant totaling $217,761 through the Maryland Industrial Partnerships Program (MIPS). With the grant, researchers at Rexahn and the University of Maryland Baltimore (UMB), will continue their joint development of polymer-drug conjugates for cancer therapy, for the targeted delivery of cancer drugs.
